Green Tea in Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Clinical Trial

Abstract

Objectives: Antioxidant treatment with Iron chelating agents is one of the suggested treatments for fatty liver disease, which has become an important health problem in the recent decades. In this study the authors evaluated the general antioxidant, iron chelating, and sugar and fat absorption characteristics of green tea. Methods: Patients with non-alcoholic fatty liver disease were randomly assigned to 2 groups for a double blind clinical trial. Patients in the intervention group received 550 milligrams of green tea tablets daily as well as nutritional education for 3 months. The control group received the same protocol with green tea replaced with placebo tablets. Results: After 3 months, 45 participants (21 in the intervention and 24 in the placebo group) completed the follow-up. The change in body mass index (BMI), aspartate aminotransferase (AST), and fasting blood sugar (FBS) was significantly different between the 2 groups, while the change in total iron binding capacity (TIBC), ferritin, alanine transaminase (ALT), HOMA, and weight did not show a significant difference. Conclusions:The difference between the 2 groups was mainly observed in anthropometrics, liver enzyme, and metabolic indicators, although the difference might not have been highlighted due to the effectiveness of routine treatments, that both groups received.

Green tea as a safe alternative approach for nonalcoholic fatty liver treatment: A systematic review and meta‐analysis of clinical trials

“…Six eligible studies comprising 265 participants with a mean age of 55 were included in the systematic review and meta‐analysis. Studies were conducted in Japan (Fukuzawa et al, ; Sakata et al, ; Sakata, Nakamura, Torimura, Ueno, & Sata, ), Iran (Pezeshki et al, ; Tabatabaee et al, ), and Pakistan (Hussain et al, ). The duration of randomized controlled trials ranged between 84 and 180 days, and the mean dosage of green tea intervention was approximately 700 mg/day.…”

“…Due to its high content of polyphenolic components, especially catechin, epicatechin gallate, epigallocatechin-3-gallate, and epigallocatechin, green tea is utilized as a folk medicine in the treatment of various metabolic disorders including obesity, hypertension, diabetes, and cardiovascular diseases (Bøhn, Ward, Hodgson, & Croft, 2012;Hadi et al, 2017). Clinical trials that tried to evaluate the precise effects of green tea supplementation regarding the NAFLD have provided paradoxical results, and its optimal role in the clinical management of this disease has not been fully established (Hussain, Habib Ur, & Akhtar, 2017;Pezeshki, Safi, Feizi, Askari, & Karami, 2016;Tabatabaee et al, 2017).…”

The effect of green tea supplementation on obesity: A systematic review and dose–response meta‐analysis of randomized controlled trials

“…The studies involved a range of 18 to 104 participants. Chan et al, 2006;Di Pierro et al, 2009;Diepvens et al, 2005;Hovanloo et al, 2016;Hsu et al, 2008;Hsu et al, 2011;Hussain et al, 2017;Janssens, Penders, et al, 2016;Kovacs et al, 2004;Mombaini et al, 2017;Nabi et al, 2018;Rostamian & Bijeh, 2017;Soeizi et al, 2017;Suliburska et al, 2012;Tabatabaee et al, 2017;Toolsee et al, 2013;Venkatakrishnan et al, 2018;Vieira Senger et al, 2012). Most studies were rated as good quality across the Cochrane items.…”

“…Most studies were rated as good quality across the Cochrane items. For some trials, the risk of bias derived from the "blinding of participants" item (Di Pierro et al, 2009;Toolsee et al, 2013) and from "the incomplete outcome data" item (Chan et al, 2006;Hsu et al, 2008;Mombaini et al, 2017;Nabi et al, 2018;Tabatabaee et al, 2017;Venkatakrishnan et al, 2018). −1.78 kg, 95% CI: −2.80, −0.75, p = .001) with no significant heterogeneity among the studies (I 2 = 19%, p = .203) ( Figure 1).…”

Efecto de la cúrcuma y té verde sobre el riesgo cardiometabólico. Revisión sistemática

“…En un ensayo clínico aplicado en pacientes con NAFDL con 550 mg de extracto té verde, durante doce semanas. pese a que se observaron efectos benéficos en medidas antropométricas, enzimas hepáticas e indicadores metabólicos (279) , las diferencias con el grupo control no fueron tan resaltantes debido a que ambos grupos continuaron con el tratamiento efectivo de rutina. Contrario a ese resultado, en dosis de 379 mg incluidas en el análisis de esta revisión, se observaron diferencias significativas en la reducción de triglicéridos, (p<0,05), colesterol total (p<0,01), LDL (p<0,001), glucosa en ayunas (p<0,05) y un incremento significativo en HDL (p<0,001), en el mismo tiempo de intervención (244) , de doce meses en adultos con BMI >30 kg/m 2 .…”